TY - JOUR
T1 - Nimodipine after aneurysmal subarachnoid hemorrhage
T2 - Fourteen-day course for patients that meet criteria for early hospital discharge
AU - Sokolowski, Jennifer D.
AU - Chen, Ching Jen
AU - Soldozy, Sauson
AU - Mastorakos, Panagiotis
AU - Burke, Rebecca M.
AU - Nguyen, Julia M.
AU - Myers, Kristin M.
AU - Kalani, M. Yashar S.
AU - Park, Min S.
N1 - Funding Information:
Funding from the Neurosurgery Research and Education Foundation, United States of America, purchased statistical software used in the study. The funding source had no role study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.
Publisher Copyright:
© 2020 Elsevier B.V.
PY - 2021/1
Y1 - 2021/1
N2 - Background: Randomized-controlled trials and meta-analyses showed nimodipine use after aneurysmal subarachnoid hemorrhage (aSAH) leads to reduction in incidence of cerebral infarction, persistent neurological deficits, and poor outcomes. Trials administered it for 21 days; however, we assessed whether a shorter duration might be reasonable for a subset of patients. Methods: We performed a retrospective single-center study to compare outcomes between patients who received ≤14 days, 15–20 days or ≥21 days of nimodipine. Primary outcome was defined as rate of good functional outcome at final follow-up, assessed using dichotomized modified Rankin Score (mRS). Secondary outcomes included median mRS at follow-up, discharge disposition, and readmission for stroke or vasospasm. Results: 195 patients were included: 101 patients received nimodipine for ≤14 days, 72 patients for 15–20 days, and 22 patients for ≥21 days. There were differences in baseline characteristics of the groups. The shorter duration groups had higher admission GCS score (GCS 15 for ≤14 days, GCS 13 for 15–20 days, GCS 8 for ≥21 days, p = 0.003) and lower Hunt-Hess grade (2 for ≤14 days, 3 for 15–20 days, 4 for ≥21 days, p = 0.001). Of the group of patients that received ≤14 days of nimodipine, 3 patients (3%) were readmitted for concerns for possible stroke or vasospasm, but they did not experience worsening of their functional status related to this. Conclusion: Our data suggests a more limited 14-day course of nimodipine therapy after aSAH may be reasonable and efficacious in patients with higher GCS and lower Hunt-Hess grade on presentation.
AB - Background: Randomized-controlled trials and meta-analyses showed nimodipine use after aneurysmal subarachnoid hemorrhage (aSAH) leads to reduction in incidence of cerebral infarction, persistent neurological deficits, and poor outcomes. Trials administered it for 21 days; however, we assessed whether a shorter duration might be reasonable for a subset of patients. Methods: We performed a retrospective single-center study to compare outcomes between patients who received ≤14 days, 15–20 days or ≥21 days of nimodipine. Primary outcome was defined as rate of good functional outcome at final follow-up, assessed using dichotomized modified Rankin Score (mRS). Secondary outcomes included median mRS at follow-up, discharge disposition, and readmission for stroke or vasospasm. Results: 195 patients were included: 101 patients received nimodipine for ≤14 days, 72 patients for 15–20 days, and 22 patients for ≥21 days. There were differences in baseline characteristics of the groups. The shorter duration groups had higher admission GCS score (GCS 15 for ≤14 days, GCS 13 for 15–20 days, GCS 8 for ≥21 days, p = 0.003) and lower Hunt-Hess grade (2 for ≤14 days, 3 for 15–20 days, 4 for ≥21 days, p = 0.001). Of the group of patients that received ≤14 days of nimodipine, 3 patients (3%) were readmitted for concerns for possible stroke or vasospasm, but they did not experience worsening of their functional status related to this. Conclusion: Our data suggests a more limited 14-day course of nimodipine therapy after aSAH may be reasonable and efficacious in patients with higher GCS and lower Hunt-Hess grade on presentation.
KW - Cerebral aneurysm
KW - Intracranial hemorrhage
KW - Nimodipine
KW - Stroke
KW - Subarachnoid hemorrhage
UR - http://www.scopus.com/inward/record.url?scp=85092757760&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85092757760&partnerID=8YFLogxK
U2 - 10.1016/j.clineuro.2020.106299
DO - 10.1016/j.clineuro.2020.106299
M3 - Article
C2 - 33092929
AN - SCOPUS:85092757760
SN - 0303-8467
VL - 200
JO - Clinical Neurology and Neurosurgery
JF - Clinical Neurology and Neurosurgery
M1 - 106299
ER -